2018年3月20日
Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report.
BMC cancer
- ,
- ,
- 巻
- 18
- 号
- 1
- 開始ページ
- 302
- 終了ページ
- 302
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1186/s12885-018-4212-1
- 出版者・発行元
- BioMed Central Ltd.
BACKGROUND: Currently, immune checkpoint (ICP) inhibitors are essential drugs for the treatment of non-small cell lung cancer (NSCLC). However, in patients previously treated with ICP inhibitors, the efficacy and safety of re-challenging the same or another ICP inhibitor remain unclear. CASE PRESENTATION: We present the case of a patient treated with nivolumab for advanced NSCLC who was previously treated with an ICP inhibitor as the first-line chemotherapy along with heavy cytotoxic chemotherapy. After the failure of five lines of chemotherapy, 3 cycles of nivolumab, as the ICP inhibitor re-challenge, the patient achieved a partial response. CONCLUSIONS: This case might suggest that re-challenging an ICP inhibitor could be clinically active in selected patients with advanced NSCLC who progress after achieving an initial clinical benefit with an ICP inhibitor.
- リンク情報
- ID情報
-
- DOI : 10.1186/s12885-018-4212-1
- ISSN : 1471-2407
- ORCIDのPut Code : 65678865
- PubMed ID : 29554874
- PubMed Central 記事ID : PMC5859734
- SCOPUS ID : 85044221279